シェーグレン症候群患者に対する唾液分泌促進薬の有効性と副作用の検討～セビメリン塩酸塩とピロカルピンと塩酸塩の比較～

DOI Web Site Web Site 被引用文献1件 参考文献3件
  • 篠崎 昌一
    九州大学大学院歯学研究院口腔顎顔面病態学講座顎顔面腫瘍制御学分野
  • 森山 雅文
    九州大学大学院歯学研究院口腔顎顔面病態学講座顎顔面腫瘍制御学分野
  • 林田 淳之介
    九州大学大学院歯学研究院口腔顎顔面病態学講座顎顔面腫瘍制御学分野
  • 田中 昭彦
    九州大学大学院歯学研究院口腔顎顔面病態学講座顎顔面腫瘍制御学分野
  • 前原 隆
    九州大学大学院歯学研究院口腔顎顔面病態学講座顎顔面腫瘍制御学分野
  • 古川 祥子
    九州大学大学院歯学研究院口腔顎顔面病態学講座顎顔面腫瘍制御学分野
  • 太田 美穂
    九州大学大学院歯学研究院口腔顎顔面病態学講座顎顔面腫瘍制御学分野
  • 今林 佑美
    九州大学大学院歯学研究院口腔顎顔面病態学講座顎顔面腫瘍制御学分野
  • 中村 誠司
    九州大学大学院歯学研究院口腔顎顔面病態学講座顎顔面腫瘍制御学分野

書誌事項

タイトル別名
  • A study of the effectiveness and side effects of salivation-inducers in patients with Sjögren’s syndrome ～ Comparison between cevimeline hydrochloride and pilocarpine hydrochloride ～
  • シェーグレン ショウコウグン カンジャ ニ タイスル ダエキ ブンピ ソクシンヤク ノ ユウコウセイ ト フクサヨウ ノ ケントウ : セビメリン エンサンエン ト ピロカルピン ト エンサンエン ノ ヒカク

この論文をさがす

抄録

Objectives: Cevimeline hydrochloride (CH) and pilocarpine hydrochloride (PH) are recognized as salivation-inducers with a high affinity for M3 muscarinic receptors. However, these drugs have a high frequency of side effects, including digestive symptoms and hyperhidrosis. We compared the effectiveness and side effects of these two drugs before and after a medication change.<br>Materials and Methods: Seventy-six patients with Sjögren's syndrome were divided into the following four groups: 1) CH group, CH was administered for 12 months; 2) PH group, PH was administered for 12 months; 3) CH-PH group, CH was administered for 6 months followed by PH for 6 months; 4) PH-CH group, PH was administered for 6 months followed by CH for 6 months. We measured the salivary flow rate and recorded the subjective symptoms in each group.<br>Results: In each group, stimulated whole saliva (SWS) and unstimulated whole saliva (UWS) significantly increased after 3 months and 6 months, respectively, and subjective symptoms improved after 3 months. The incremental changes in both SWS and UWS did not differ significantly between the groups. The CH and PH groups both had digestive symptoms (32.3% and 32.1%, respectively) and hyperhidrosis (29.0% and 39.3%, respectively). We found no significant difference in salivary flow rate or subjective symptoms after the medication change. However, the frequencies of side effects in the CH-PH and PH-CH groups decreased significantly for both digestive symptoms (9.7% and 10.7%, respectively) and hyperhidrosis (25.8% and 14.3%, respectively).<br>Conclusions: After changing the salivation-inducing drug, there was no significant difference in salivary function or subjective symptoms, while the frequency of side effects markedly decreased. These results suggest that changing the salivation-inducing drug effectively reduces side effects.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (3)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ